NO20015481L - Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer - Google Patents

Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer

Info

Publication number
NO20015481L
NO20015481L NO20015481A NO20015481A NO20015481L NO 20015481 L NO20015481 L NO 20015481L NO 20015481 A NO20015481 A NO 20015481A NO 20015481 A NO20015481 A NO 20015481A NO 20015481 L NO20015481 L NO 20015481L
Authority
NO
Norway
Prior art keywords
treatment
mbl
mannan
prophylaxis
binding lectin
Prior art date
Application number
NO20015481A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015481D0 (no
Inventor
Steffen Thiel
Jens Christian Jensenius
Original Assignee
Jens Christian Jensenius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jens Christian Jensenius filed Critical Jens Christian Jensenius
Publication of NO20015481D0 publication Critical patent/NO20015481D0/no
Publication of NO20015481L publication Critical patent/NO20015481L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20015481A 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer NO20015481L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DKPA199901508 1999-10-20
PCT/DK2000/000247 WO2000069894A2 (en) 1999-05-14 2000-05-10 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals

Publications (2)

Publication Number Publication Date
NO20015481D0 NO20015481D0 (no) 2001-11-08
NO20015481L true NO20015481L (no) 2002-01-11

Family

ID=26064419

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015481A NO20015481L (no) 1999-05-14 2001-11-08 Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer
NO20015506A NO20015506L (no) 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20015506A NO20015506L (no) 1999-05-14 2001-11-09 Rekombinant humant mannanbindende lectin

Country Status (15)

Country Link
US (5) US6562784B1 (de)
EP (3) EP1402897B1 (de)
JP (2) JP2002544286A (de)
CN (2) CN1359420A (de)
AT (3) ATE336260T1 (de)
AU (2) AU781135B2 (de)
CA (2) CA2372435A1 (de)
DE (3) DE60030173T2 (de)
DK (3) DK1181038T3 (de)
ES (3) ES2219336T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515718A (de)
PT (3) PT1402897E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000069894A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
DE60030173T2 (de) * 1999-05-14 2007-08-23 Steffen Thiel Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
WO2002005833A1 (en) * 2000-07-13 2002-01-24 Natimmune A/S MANNAN-BINDING LECTIN (MBL) TREATMENT OF INFECTIONS IN INDIVIDUALS TREATED WITH TNF-αinhibitors
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
WO2002041913A1 (en) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants
CN101011573A (zh) 2001-07-23 2007-08-08 纳蒂芒公司 高分子量凝集素的生产
JP4051030B2 (ja) * 2001-08-31 2008-02-20 扶桑薬品工業株式会社 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途
ES2254759T3 (es) * 2001-10-19 2006-06-16 Natimmune A/S Aislamiento de lectinas.
AU2003215524A1 (en) * 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
EP1501537A4 (de) * 2002-04-24 2008-01-16 Queensland Inst Med Res Mannose bindendes lectin und seine verwendungszwecke
JPWO2004002511A1 (ja) * 2002-06-28 2005-10-27 扶桑薬品工業株式会社 抗ｈｉｖ剤
AU2003260286A1 (en) * 2002-09-10 2004-04-30 Natlmmune A/S Collectin-complement activating protein chimeras
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
WO2004064608A2 (en) * 2003-01-17 2004-08-05 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
CA2555989A1 (en) * 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
AU2005222381B2 (en) 2004-03-09 2010-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVL, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
US20090247454A1 (en) * 2004-09-29 2009-10-01 Mellitus, S.L. Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease
WO2006067807A1 (en) * 2004-12-23 2006-06-29 Council Of Scientific And Industrial Research Pharmaceutical composition for the treatment of invasive pulmonary aspergillosis
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
EP1874333A2 (de) * 2005-04-11 2008-01-09 Natimmune A/S Mannan-bindungslectin (mbl) bei der behandlung von immunschwäche im zusammenhang mit krebs
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
CN101939531A (zh) * 2008-01-16 2011-01-05 苏佩尔帕尔汽车工业和贸易有限公司 用于重型发动机平台的电动燃料泵
WO2009126346A2 (en) * 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
SG10201503351RA (en) * 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
WO2011100528A2 (en) 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP3327090A1 (de) 2012-07-18 2018-05-30 President and Fellows of Harvard College Modifizierung von oberflächen zur gleichzeitigen abweisung und gezielten bindung gewünschter gruppen
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
CA3024490A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
FI900808A7 (fi) * 1987-08-20 1990-02-19 Childrens Medical Center Ihmisen mannoosia sitova proteiini
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
EP0856580A4 (de) 1995-08-17 2001-02-07 Fuso Pharmaceutical Ind Rekombinantes conglutinin und verfahren zu dessen herstellung
JP3990736B2 (ja) 1997-08-21 2007-10-17 タカラバイオ株式会社 制がん剤
DK1084143T3 (da) * 1998-06-10 2006-12-27 Statens Seruminstitut Oprensningsproces til fremstilling af mannanbindende lectin og et medicinsk MBL-produkt
DE60030173T2 (de) * 1999-05-14 2007-08-23 Steffen Thiel Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten

Also Published As

Publication number Publication date
NO20015506L (no) 2002-01-09
DE60030173T2 (de) 2007-08-23
US7439224B2 (en) 2008-10-21
PT1181363E (pt) 2007-05-31
DK1181363T3 (da) 2007-05-29
AU779404B2 (en) 2005-01-20
CA2372128A1 (en) 2000-11-23
DE60033147T2 (de) 2007-12-13
US7202207B2 (en) 2007-04-10
AU4393500A (en) 2000-12-05
US20070197428A1 (en) 2007-08-23
JP2002544286A (ja) 2002-12-24
PT1181038E (pt) 2004-08-31
WO2000069894A2 (en) 2000-11-23
ATE352620T1 (de) 2007-02-15
ATE264111T1 (de) 2004-04-15
AU781135B2 (en) 2005-05-05
EP1181038B1 (de) 2004-04-14
DE60009896T2 (de) 2005-04-21
RU2005125625A (ru) 2007-02-20
EP1402897A3 (de) 2004-06-30
WO2000069894A3 (en) 2001-02-08
NO20015506D0 (no) 2001-11-09
NZ515717A (en) 2004-01-30
NZ515718A (en) 2004-03-26
DE60030173D1 (de) 2006-09-28
NO20015481D0 (no) 2001-11-08
JP2002543837A (ja) 2002-12-24
ES2281341T3 (es) 2007-10-01
US6846649B1 (en) 2005-01-25
ATE336260T1 (de) 2006-09-15
EP1402897B1 (de) 2006-08-16
EP1181363B1 (de) 2007-01-24
DK1402897T3 (da) 2006-12-27
PT1402897E (pt) 2007-01-31
US20030191052A1 (en) 2003-10-09
DE60033147D1 (de) 2007-03-15
CN1359420A (zh) 2002-07-17
CA2372435A1 (en) 2000-11-23
ES2271468T3 (es) 2007-04-16
DK1181038T3 (da) 2004-08-09
EP1181038A2 (de) 2002-02-27
DE60009896D1 (de) 2004-05-19
EP1181363A1 (de) 2002-02-27
ES2219336T3 (es) 2004-12-01
AU4393600A (en) 2000-12-05
EP1402897A2 (de) 2004-03-31
CN1359298A (zh) 2002-07-17
WO2000070043A1 (en) 2000-11-23
US20040229212A1 (en) 2004-11-18
RU2292217C2 (ru) 2007-01-27
US6562784B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
NO20015481L (no) Nye indikasjoner på mannanbindende lectin (MBL) ved behandlingen av immunkompromitterte individer
MY106315A (en) Pharmaceutical agents
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
SE0102315D0 (sv) Compounds
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DK1455605T3 (da) Læskedrikerstatning
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
EP1040830A4 (de) Heilmittel für neurodegenerative krankheiten
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
BG105302A (en) Means for improving cognition
DE60109632D1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
AU4568400A (en) Sphingomyelinase inhibitor
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
WO2003042240A3 (en) Polypeptides of pseudomonas aeruginosa
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
PL355113A1 (en) Novel fusidic acid derivatives
WO2002097075A3 (en) Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties